Reviva Pharmaceuticals Holdings, Inc. - Common Stock (RVPH)
1.8900
+0.0500 (2.72%)
Reviva Pharmaceuticals Holdings Inc. is a biopharmaceutical company focused on developing innovative therapeutic solutions for conditions with significant unmet medical needs
The company primarily concentrates on advancing its proprietary drug candidates through clinical trials to address psychiatric, neurological, and inflammatory disorders. Reviva utilizes its expertise in pharmacology to create novel treatment options that aim to improve the lives of patients by targeting specific mechanisms of disease while minimizing side effects associated with traditional therapies. Through its research and development efforts, Reviva seeks to make meaningful contributions to the field of medicine and enhance patient outcomes.
WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQRVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public.
WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQRVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public.
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQRVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reviva Pharmaceuticals Holdings, Inc. (“Reviva” or the “Company”) (NASDAQRVPH) on behalf of Reviva stockholders. Our investigation concerns whether Reviva has violated the federal securities laws and/or engaged in other unlawful business practices.
CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQRVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present at the Webull LIVE! Virtual Healthcare Investment Webinar on Wednesday, January 17, 2024.
NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held December 14th. This event is sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend.
CUPERTINO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQRVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will participate live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on December 14th, 2023. Dr. Bhat will engage in a “CEO Chat” session with John Vandermosten, Senior Biotechnology Analyst with Zacks Small-Cap Research.
Reviva Pharmaceuticals Holdings Inc (NASDAQRVPH) shares are surging after the company released topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in
